tiprankstipranks
Knight Therapeutics sees FY24 revenue C$355M-C$365M
PremiumThe FlyKnight Therapeutics sees FY24 revenue C$355M-C$365M
20d ago
KHTRF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
KHTRF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
22d ago
Knight Therapeutics announces approval of Minjuvi in Mexico
Premium
The Fly
Knight Therapeutics announces approval of Minjuvi in Mexico
1M ago
Knight Therapeutics reports Q2 EPS (C$0.02) vs. C$0.02 last year
PremiumThe FlyKnight Therapeutics reports Q2 EPS (C$0.02) vs. C$0.02 last year
4M ago
Knight Therapeutics Hits Record Q2 Revenues
Premium
Company Announcements
Knight Therapeutics Hits Record Q2 Revenues
4M ago
Is KHTRF a Buy, Before Earnings?
Premium
Pre-Earnings
Is KHTRF a Buy, Before Earnings?
4M ago
Knight Therapeutics Announces Q1 Growth and Expansion
PremiumCompany AnnouncementsKnight Therapeutics Announces Q1 Growth and Expansion
7M ago
Knight Therapeutics Shareholders Back Directors and Auditors
Premium
Company Announcements
Knight Therapeutics Shareholders Back Directors and Auditors
7M ago
Knight Therapeutics price target raised to C$5.40 from C$5.25 at Stifel
Premium
The Fly
Knight Therapeutics price target raised to C$5.40 from C$5.25 at Stifel
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100